[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-402163-105":59,"doc-detail-402163-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","british-association-for-sexual-health-and-hivbritish-hiv-association-guidelines-on-the-use-of-hiv-pre-exposure-prophylaxis-prep-2025","British Association for Sexual Health and HIV/British HIV Association Guidelines on the Use of HIV Pre-Exposure Prophylaxis (PrEP) 2025","","Guidelines for the use of HIV pre-exposure prophylaxis (PrEP) in 2025, prepared by the British Association for Sexual Health and HIV and the British HIV Association. The document covers executive summary recommendations and detailed sections on PrEP equity and access, efficacy and safety, suitability and risk assessment, baseline testing and clinical management, and ongoing monitoring. It further addresses starting and stopping specific PrEP regimens, post-exposure prophylaxis in PrEP users, access to generic PrEP online, and new therapies, using defined methods and terminology.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/british-association-for-sexual-health-and-hivbritish-hiv-association-guidelines-on-the-use-of-hiv-pre-exposure-prophylaxis-prep-2025/402163/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/british-association-for-sexual-health-and-hivbritish-hiv-association-guidelines-on-the-use-of-hiv-pre-exposure-prophylaxis-prep-2025/402163.png","ImageObject",300,407,{"name":92,"@type":93},"AfterMidnight","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-02","2026-09-27",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Who developed the 2025 PrEP guidelines and who contributed to the writing group?","Question",{"text":112,"@type":113},"The guidelines are prepared by the British Association for Sexual Health and HIV and the British HIV Association. They list writing group co-chairs, BASHH editors, and multiple group members, along with acknowledgements to the BHIVA guidelines coordinator.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What key topics do the recommendations cover across the main sections?",{"text":117,"@type":113},"The recommendations span PrEP equity and access, PrEP efficacy and safety, PrEP suitability and risk assessment, baseline testing and clinical management, and ongoing monitoring. They also include guidance on starting and stopping TD-FTC and TAF-FTC PrEP, PEP in PrEP users, buying generic PrEP online, and new therapies.",{"name":119,"@type":110,"acceptedAnswer":120},"What methods are used to develop the guidelines?",{"text":121,"@type":113},"The document describes methods including a search strategy, the GRADE system, good practice points (GPPs), writing group and stakeholder involvement with feedback, and terminology definitions used throughout the guideline.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},402163,1790871326,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":4},962090896061,"https://ap-avatar.wpscdn.com/davatar_9964176cb1d06d4a9deccf72a44ae3dc","British Association for Sexual Health and HIV/British HIV Association guidelines on the use of HIV pre-exposure prophylaxis (PrEP) 2025  \nWriting group  \nCo-chairs  \nMichael Brady, Kings College Hospital NHS Foundation Trust Dan Clutterbuck, NHS Lothian and University of Edinburgh  \nAlison Rodger, University College London and Royal Free London NHS Foundation Trust  \nBASHH editors  \nNick Medland, The Kirby Institute, University of New South Wales Ann Sullivan, Chelsea and Westminster Hospital NHS Foundation Trust  \nGroup members  \nVanessa Apea, Barts Health NHS Trust Flav Coukan, University College London  \nClaudia Estcourt, Glasgow Caledonian University and University College London Sarah Fidler, Imperial College London  \nNigel Field, University College London  \nDaniel Fluskey (replacing Adam Freedman), National AIDS Trust  \nJulie Fox, Kings College London and Guy’s and St Thomas’ NHS Foundation Trust Sheena McCormack, MRC Clinical Trials Unit at University College London  \nWill Nutland, The Love Tank  \nJuddy Otti, Africa Advocacy Foundation Greg Owen, Terrence Higgins Trust Erica Pool, University College London  \nKillian Quinn, King's College Hospital NHS Foundation Trust  \nJohn Saunders, UK Health Security Agency and University College London Victoria Tittle, Chelsea and Westminster Hospital NHS Foundation Trust Daniel Trotman, King's College Hospital NHS Foundation Trust  \nIngrid Young, University of Edinburgh  \nWith many thanks to Dr Catherine Nieman Sims for her endless support and hard work as BHIVA guidelines coordinator.  \nDedication  \nThese guidelines are dedicated to our late colleagues Dr Nick Medland and Dr Mags Portman. They made valuable contributions to the field and both are sorely missed.  \nContents  \nExecutive summary ................................................................................................................... 5  \nReferences............................................................................................................................. 5  \nSummary of recommendations ................................................................................................. 6  \nRecommendations for section 3 PrEP equity and access ..................................................... 6  \nRecommendations for section 4 PrEP efficacy and safety.................................................... 6  \nRecommendations for section 5 PrEP suitability and risk assessment................................. 7  \nRecommendations for section 6 Baseline testing and clinical management ....................... 9  \nRecommendations for section 7 On-going clinical management and monitoring ............. 11  \nRecommendations for section 8.1 Starting and stopping TD-FTC and TAF-FTC PrEP......... 13  \nRecommendations for section 8.2 PEP in PrEP users ......................................................... 14  \nRecommendations for section 9 Buying generic PrEP online ............................................. 15  \nRecommendations for section 10 New therapies............................................................... 16  \n1 Objectives ............................................................................................................................. 18  \n1.1 Inclusivity ...................................................................................................................... 18  \n1.2 Language ....................................................................................................................... 18  \n2 Methods ............................................................................................................................... 19  \n2.1 Search strategy.............................................................................................................. 19  \n2.2 GRADE system ............................................................................................................... 19  \n2.2.1 Good practice points (GPPs) ................................","cbCaisnlsa3QAnR0","https://ap.wps.com/l/cbCaisnlsa3QAnR0","pdf",1720378,102,"English","# Executive summary\n## Summary of recommendations\n# Recommendations for section 3 PrEP equity and access\n# Recommendations for section 4 PrEP efficacy and safety\n# Recommendations for section 5 PrEP suitability and risk assessment\n# Recommendations for section 6 Baseline testing and clinical management\n# Recommendations for section 7 On-going clinical management and monitoring\n# Recommendations for section 8.1 Starting and stopping TD-FTC and TAF-FTC PrEP\n# Recommendations for section 8.2 PEP in PrEP users\n# Recommendations for section 9 Buying generic PrEP online\n# Recommendations for section 10 New therapies\n# 1 Objectives\n## 1.1 Inclusivity\n## 1.2 Language\n# 2 Methods\n## 2.1 Search strategy\n## 2.2 GRADE system\n### 2.2.1 Good practice points (GPPs)\n## 2.3 Writing group, stakeholder involvement and feedback\n## 2.4 Terminology\n### 2.4.1 PrEP\n### 2.4.2 Generic preparations of tenofovir disoproxil\n### 2.4.3 PrEP dosing options\n### 2.4.4 Exposure and risk\n### 2.4.5 Condomless sex\n## 2.5 References\n# 3 PrEP equity and access\n## 3.1 Inequity in PrEP awareness and access\n## 3.2 Working towards equity within the PrEP care continuum","[{\"question\":\"Who developed the 2025 PrEP guidelines and who contributed to the writing group?\",\"answer\":\"The guidelines are prepared by the British Association for Sexual Health and HIV and the British HIV Association. They list writing group co-chairs, BASHH editors, and multiple group members, along with acknowledgements to the BHIVA guidelines coordinator.\"},{\"question\":\"What key topics do the recommendations cover across the main sections?\",\"answer\":\"The recommendations span PrEP equity and access, PrEP efficacy and safety, PrEP suitability and risk assessment, baseline testing and clinical management, and ongoing monitoring. They also include guidance on starting and stopping TD-FTC and TAF-FTC PrEP, PEP in PrEP users, buying generic PrEP online, and new therapies.\"},{\"question\":\"What methods are used to develop the guidelines?\",\"answer\":\"The document describes methods including a search strategy, the GRADE system, good practice points (GPPs), writing group and stakeholder involvement with feedback, and terminology definitions used throughout the guideline.\"}]","British Association for Sexual Health and HIV/British HIV Association Guidelines on the Use of HIV Pre-Exposure Prophylaxis (PrEP) 2025 | PDF",1790527659,257]